Understanding Genitourinary Syndrome of Menopause (GSM)
At a Glance
Genitourinary Syndrome of Menopause (GSM), formerly called postmenopausal atrophic vaginitis, is a common condition caused by low estrogen levels. It causes vaginal dryness, tissue thinning, and urinary issues. Unlike hot flashes, GSM is progressive and worsens without treatment.
If you are experiencing vaginal dryness, irritation, or new urinary issues after menopause, you might feel like your body is suddenly behaving in ways you don’t understand. It is common to feel frustrated or even embarrassed, but what you are experiencing has a medical name: Genitourinary Syndrome of Menopause (GSM) [1].
For a long time, this was called “atrophic vaginitis,” but that name was misleading because it suggested the problem was only about inflammation in the vagina [2][3]. In reality, these changes affect the entire urogenital system—the complex network of tissues including the vulva, vagina, bladder, and urethra [3][4].
Why the Name Changed
The shift to the term Genitourinary Syndrome of Menopause was a deliberate move by medical experts to better reflect the reality of the condition [1].
- More than the vagina: The old term ignored the urinary symptoms (like urgency or frequent UTIs) and external changes (vulvar irritation) that many women experience [2][3].
- Not just inflammation: The suffix “-itis” implies a temporary infection or inflammation, whereas GSM describes a collection of symptoms caused by a long-term hormonal shift [2].
- Anchored to menopause: The new name clearly links these changes to the natural decline of estrogen during the menopausal transition [3][4].
You Are Not Alone
If you feel like no one is talking about this, you’re right—but not because it’s rare. GSM is incredibly common, affecting up to 77% of postmenopausal women [5][6]. Despite how many people it affects, it is frequently under-reported and underdiagnosed [5][7]. Many women suffer in silence because they believe these changes are a “normal” part of aging that they must simply tolerate, or they feel a stigma attached to discussing urogenital health [7][8].
The Biological “Why”
The driver behind GSM is hypoestrogenism, which is the medical term for low estrogen levels [1][4]. Your urogenital tissues are highly sensitive to estrogen; when levels drop, several biological changes occur:
- Tissue Thinning: The lining of the vagina and urethra becomes thinner, more fragile, and less elastic [9][4].
- Reduced Lubrication: The natural moisture and blood flow to these areas decrease, leading to dryness and irritation [9].
- Altered Balance: The healthy environment of the vagina changes, which can sometimes make the area more prone to infections or urinary discomfort [9][10].
A Chronic and Progressive Journey
It is vital to understand that GSM is different from other menopause symptoms like hot flashes [11]. While hot flashes often peak and then gradually fade away for many people, GSM is chronic and progressive [11][4].
“Progressive” means that without proactive management, the tissue changes typically do not resolve on their own; instead, they may continue to worsen over time as the body remains in a low-estrogen state [11][12]. This is why early recognition and communication with your healthcare provider are so important—treating the symptoms early can help preserve the health and function of these tissues for the long term [13][6].
You do not have to “just live with it.” Understanding that this is a recognized medical condition is the first step toward finding relief and improving your quality of life [14][6].
Common questions in this guide
What is the difference between atrophic vaginitis and GSM?
Why do vaginal dryness and urinary issues happen after menopause?
Will my GSM symptoms eventually go away on their own?
How does a doctor diagnose Genitourinary Syndrome of Menopause?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Causes of symptoms
Is it low estrogen that causes the thinning and dryness I notice?
Changes over time
Will these changes keep getting worse over time without treatment?
Urinary symptoms
Could frequent UTIs and urgency be part of GSM?
Get notified when new evidence is published on postmenopausal atrophic vaginitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.
Angelou K, Grigoriadis T, Diakosavvas M, et al.
Cureus 2020; (12(4)):e7586 doi:10.7759/cureus.7586.
PMID: 32399320 - 2
What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?
Nappi RE, Gardella B
Expert opinion on pharmacotherapy 2019; (20(7)):777-779 doi:10.1080/14656566.2019.1582644.
PMID: 30806100 - 3
Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).
Simon JA, Nappi RE, Chedraui P, et al.
Sexual medicine reviews 2026; (14(1)) doi:10.1093/sxmrev/qeaf055.
PMID: 40981832 - 4
Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.
Kovacevic N, Cilensek I, Merlo S, Segedin B
Radiology and oncology 2023; (57(3)):292-298 doi:10.2478/raon-2023-0038.
PMID: 37494601 - 5
How to help patients navigate genitourinary syndrome of menopause.
Trischuk T, Visentin J, Morissette R
Canadian family physician Medecin de famille canadien 2024; (70(11-12)):710-714 doi:10.46747/cfp.701112710.
PMID: 39638389 - 6
Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer.
Ferguson D, Pederson H, Kling JM
Drugs & aging 2026; (43(3)):211-221 doi:10.1007/s40266-026-01287-9.
PMID: 41758440 - 7
Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.
Cuccu I, Golia D'Augè T, Firulli I, et al.
Life (Basel, Switzerland) 2024; (14(11)) doi:10.3390/life14111504.
PMID: 39598302 - 8
The Enablers and Barriers to Accessing Women's Health and Wellbeing Services for Women Aged 40-65 Years: A Qualitative Study.
Simmons K, Hyde J, Harmanci D, et al.
Community health equity research & policy 2026; (46(4)):413-431 doi:10.1177/2752535X251358919.
PMID: 40653685 - 9
The effect of pathophysiological changes in the vaginal milieu on the signs and symptoms of genitourinary syndrome of menopause (GSM).
Qi W, Li H, Wang C, et al.
Menopause (New York, N.Y.) 2020; (28(1)):102-108 doi:10.1097/GME.0000000000001644.
PMID: 32810079 - 10
Genitourinary syndrome of menopause: in their own words-development of a new patient-reported outcome measure.
Kling JM, Faubion SS
Menopause (New York, N.Y.) 2019; (26(4)):335-336 doi:10.1097/GME.0000000000001309.
PMID: 30724847 - 11
Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.
Kaunitz AM, Pinkerton JV, Manson JE
Menopause (New York, N.Y.) 2019; (26(4)):338-340 doi:10.1097/GME.0000000000001313.
PMID: 30789455 - 12
Genitourinary syndrome of menopause: effects on related factors, quality of life, and self-care power.
Karakoç H, Uçtu AK, Özerdoğan N
Przeglad menopauzalny = Menopause review 2019; (18(1)):15-22 doi:10.5114/pm.2019.84152.
PMID: 31114453 - 13
Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.
Nappi RE, Martini E, Cucinella L, et al.
Frontiers in endocrinology 2019; (10()):561 doi:10.3389/fendo.2019.00561.
PMID: 31496993 - 14
The WISDOM survey: toward wiser care of women with vulvovaginal atrophy.
Shifren JL
Menopause (New York, N.Y.) 2019; (26(2)):115-117 doi:10.1097/GME.0000000000001281.
PMID: 30531445
This page provides educational information about Genitourinary Syndrome of Menopause (GSM) and is not a substitute for professional medical advice. Always talk to your healthcare provider about your specific symptoms and long-term management options.